Shin-Cheh Chen

Articles by Shin-Cheh Chen

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

ByNagi El Saghir,Yoon Sim Yap,Yesim Eralp,Seock-Ah Im,Hamdy Abdel Azim,Julie Rihani,Nikita Volkov,Shin-Cheh Chen,Hakan Harputluoglu,Patrapim Sunpaweravong,Yuan-Ching Chang,Teresa Delgar Alfaro,Jiwen Wu,Huilin Hu,Melissa Gao,Yen-Shen Lu
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

ByMatthew P. Goetz, MD,Masakazu Toi,Jens Huober, MD,Joohyuk Sohn,Oliver Trédan,In Hae Park,Mario Campone,Shin-Cheh Chen,Luis Manuel Manso,Shani Paluch-Shimon,Orit C. Freedman,Joyce A. O’Shaughnessy,Xavier Pivot,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Antonio Llombart,Valérie André,Abhijoy Saha,Gertjan van Hal,Ashwin Shahir,Hiroji Iwata,Stephen R.D. Johnston

Latest Updated Articles